Financhill
Sell
16

PFE Quote, Financials, Valuation and Earnings

Last price:
$22.05
Seasonality move :
1.65%
Day range:
$22.10 - $22.55
52-week range:
$20.92 - $31.54
Dividend yield:
7.63%
P/E ratio:
15.70x
P/S ratio:
1.98x
P/B ratio:
1.42x
Volume:
51.8M
Avg. volume:
61.3M
1-year change:
-12.9%
Market cap:
$125.5B
Revenue:
$63.6B
EPS (TTM):
$1.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PFE
Pfizer
$14.2B $0.70 1.91% 5655.4% $30.16
AMGN
Amgen
$8B $4.27 5.51% 285.64% $317.12
ARVN
Arvinas
$41.9M -$0.97 71.95% -5.19% $36.22
GILD
Gilead Sciences
$6.8B $1.75 -0.01% 50.66% $112.74
MRNA
Moderna
$125.9M -$3.10 -19.37% -0.05% $51.14
VKTX
Viking Therapeutics
-- -$0.31 -- -21.87% $95.44
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PFE
Pfizer
$22.14 $30.16 $125.5B 15.70x $0.43 7.63% 1.98x
AMGN
Amgen
$277.29 $317.12 $149B 36.73x $2.38 3.29% 4.48x
ARVN
Arvinas
$8.60 $36.22 $591.4M -- $0.00 0% 2.35x
GILD
Gilead Sciences
$104.54 $112.74 $130.2B 282.54x $0.79 2.97% 4.57x
MRNA
Moderna
$24.72 $51.14 $9.6B -- $0.00 0% 3.00x
VKTX
Viking Therapeutics
$23.94 $95.44 $2.7B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PFE
Pfizer
41.92% 0.587 43.87% 0.82x
AMGN
Amgen
91.09% 0.284 43.85% 0.84x
ARVN
Arvinas
0.11% 3.556 0.05% 4.58x
GILD
Gilead Sciences
58.02% 0.600 23.22% 1.33x
MRNA
Moderna
-- 0.004 -- 3.45x
VKTX
Viking Therapeutics
-- -0.677 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
ARVN
Arvinas
-- -$58.2M -32.92% -32.96% -98.31% -$84.4M
GILD
Gilead Sciences
$6B $2.4B 1.09% 2.5% 31.92% $2.8B
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Pfizer vs. Competitors

  • Which has Higher Returns PFE or AMGN?

    Amgen has a net margin of 2.31% compared to Pfizer's net margin of 6.9%. Pfizer's return on equity of 8.91% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About PFE or AMGN?

    Pfizer has a consensus price target of $30.16, signalling upside risk potential of 36.24%. On the other hand Amgen has an analysts' consensus of $317.12 which suggests that it could grow by 14.37%. Given that Pfizer has higher upside potential than Amgen, analysts believe Pfizer is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 14 1
    AMGN
    Amgen
    9 14 2
  • Is PFE or AMGN More Risky?

    Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

  • Which is a Better Dividend Stock PFE or AMGN?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Amgen offers a yield of 3.29% to investors and pays a quarterly dividend of $2.38 per share. Pfizer pays 118.44% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PFE or AMGN?

    Pfizer quarterly revenues are $17.8B, which are larger than Amgen quarterly revenues of $9.1B. Pfizer's net income of $410M is lower than Amgen's net income of $627M. Notably, Pfizer's price-to-earnings ratio is 15.70x while Amgen's PE ratio is 36.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.98x versus 4.48x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    1.98x 15.70x $17.8B $410M
    AMGN
    Amgen
    4.48x 36.73x $9.1B $627M
  • Which has Higher Returns PFE or ARVN?

    Arvinas has a net margin of 2.31% compared to Pfizer's net margin of -76.18%. Pfizer's return on equity of 8.91% beat Arvinas's return on equity of -32.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    ARVN
    Arvinas
    -- -$0.63 $562.3M
  • What do Analysts Say About PFE or ARVN?

    Pfizer has a consensus price target of $30.16, signalling upside risk potential of 36.24%. On the other hand Arvinas has an analysts' consensus of $36.22 which suggests that it could grow by 321.19%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 14 1
    ARVN
    Arvinas
    12 5 0
  • Is PFE or ARVN More Risky?

    Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Arvinas has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.541%.

  • Which is a Better Dividend Stock PFE or ARVN?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or ARVN?

    Pfizer quarterly revenues are $17.8B, which are larger than Arvinas quarterly revenues of $59.2M. Pfizer's net income of $410M is higher than Arvinas's net income of -$45.1M. Notably, Pfizer's price-to-earnings ratio is 15.70x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.98x versus 2.35x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    1.98x 15.70x $17.8B $410M
    ARVN
    Arvinas
    2.35x -- $59.2M -$45.1M
  • Which has Higher Returns PFE or GILD?

    Gilead Sciences has a net margin of 2.31% compared to Pfizer's net margin of 23.56%. Pfizer's return on equity of 8.91% beat Gilead Sciences's return on equity of 2.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    GILD
    Gilead Sciences
    79.11% $1.42 $46B
  • What do Analysts Say About PFE or GILD?

    Pfizer has a consensus price target of $30.16, signalling upside risk potential of 36.24%. On the other hand Gilead Sciences has an analysts' consensus of $112.74 which suggests that it could grow by 7.85%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 14 1
    GILD
    Gilead Sciences
    14 12 0
  • Is PFE or GILD More Risky?

    Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

  • Which is a Better Dividend Stock PFE or GILD?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Gilead Sciences offers a yield of 2.97% to investors and pays a quarterly dividend of $0.79 per share. Pfizer pays 118.44% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PFE or GILD?

    Pfizer quarterly revenues are $17.8B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Pfizer's net income of $410M is lower than Gilead Sciences's net income of $1.8B. Notably, Pfizer's price-to-earnings ratio is 15.70x while Gilead Sciences's PE ratio is 282.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.98x versus 4.57x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    1.98x 15.70x $17.8B $410M
    GILD
    Gilead Sciences
    4.57x 282.54x $7.6B $1.8B
  • Which has Higher Returns PFE or MRNA?

    Moderna has a net margin of 2.31% compared to Pfizer's net margin of -117.16%. Pfizer's return on equity of 8.91% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About PFE or MRNA?

    Pfizer has a consensus price target of $30.16, signalling upside risk potential of 36.24%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 106.9%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 14 1
    MRNA
    Moderna
    5 17 1
  • Is PFE or MRNA More Risky?

    Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

  • Which is a Better Dividend Stock PFE or MRNA?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or MRNA?

    Pfizer quarterly revenues are $17.8B, which are larger than Moderna quarterly revenues of $956M. Pfizer's net income of $410M is higher than Moderna's net income of -$1.1B. Notably, Pfizer's price-to-earnings ratio is 15.70x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.98x versus 3.00x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    1.98x 15.70x $17.8B $410M
    MRNA
    Moderna
    3.00x -- $956M -$1.1B
  • Which has Higher Returns PFE or VKTX?

    Viking Therapeutics has a net margin of 2.31% compared to Pfizer's net margin of --. Pfizer's return on equity of 8.91% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About PFE or VKTX?

    Pfizer has a consensus price target of $30.16, signalling upside risk potential of 36.24%. On the other hand Viking Therapeutics has an analysts' consensus of $95.44 which suggests that it could grow by 298.68%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 14 1
    VKTX
    Viking Therapeutics
    9 2 0
  • Is PFE or VKTX More Risky?

    Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

  • Which is a Better Dividend Stock PFE or VKTX?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.63%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or VKTX?

    Pfizer quarterly revenues are $17.8B, which are larger than Viking Therapeutics quarterly revenues of --. Pfizer's net income of $410M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Pfizer's price-to-earnings ratio is 15.70x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.98x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    1.98x 15.70x $17.8B $410M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Rocket Lab Vs Intuitive Machines Stock
Rocket Lab Vs Intuitive Machines Stock

The commercialization of outer space is now in full swing,…

Is The Trade Desk a Screaming Buy?
Is The Trade Desk a Screaming Buy?

One factor that sets programmatic advertising platform The Trade Desk…

Is IQQQ High Income ETF Good to Buy?
Is IQQQ High Income ETF Good to Buy?

The Proshares NASDAQ-100 High Income ETF (IQQQ) is a covered…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 32x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 31x

Sell
46
Is NVDA Stock a Buy?

Market Cap: $2.5T
P/E Ratio: 35x

Alerts

Sell
23
UNH alert for Apr 21

UnitedHealth Group [UNH] is down 6.42% over the past day.

Sell
30
MAN alert for Apr 21

ManpowerGroup [MAN] is down 0.22% over the past day.

Sell
24
GPN alert for Apr 21

Global Payments [GPN] is down 2.84% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock